Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR19TIF in Relapsed/Refractory B-cell Lymphoma
NCT07009002Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Jun 2025
- Primary completion
- May 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CAR19TIF in B cell lymphoma, sponsored by Chinese PLA General Hospital. Started Jun 2025; status: recruiting.
02
Drugs
CAR19TIF
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT07009002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07009002.